
China Drug-Price Negotiations Offers Glimpse Into Future for Companies in US
As drugmakers in the US steel for price negotiations ushered in by President Joe Biden’s Inflation Reduction Act,
2023-08-03 10:17

Eisai Appoints CEO’s 34-Year-Old Son to Lead Global Alzheimer Drug Program
Japanese drug giant Eisai Co. said global Alzheimer drug program officer Ivan Cheung will retire at the end
2023-07-11 11:20

Eisai Alzheimer's Drug Gets Full US Approval, Widening Access to the Therapy
Eisai Co.’s Alzheimer’s drug Leqembi gained full approval from US regulators, a move that will help widen insurance
2023-07-07 08:48

How a Japanese Drugmaker Clinched Win Over Alzheimer’s
(This story was originally published Sept. 29. On Thursday, the US Food and Drug Administration granted full approval
2023-07-07 08:46